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For the first time in modern history, worldwide total prescription drug sales 
experienced negative year-over-year growth in 2012.  In contrast to 
conventional pharmaceuticals for which negative sales growth is projected for 
several more years, sales of biologic products (those derived through 
biotechnology) grew year-over-year in 2012 and are projected to grow 
continuously through at least 2018 at a CAGR greater than 7%.  These growth 
trends reflect the relatively lower clinical failure rate for biologics vs small 
molecules; notably, the phase II failure rate of small molecules is nearly twice 
that of biologics.  The industry shift toward biologics reflects their relatively 
greater on-target efficacy and lower risk of off-target toxicity compared to 
conventional pharmaceutical drugs. 
Several prominent pharmaceutical firms have set explicit targets ranging 
from roughly 20% to greater than 75% for the biologics portions of their R&D 
pipelines.  This extent of emphasis on large molecules represents a radical 
evolution of thought from the late 90’s and early 2000’s when most major 
Pharma companies viewed biologics as niche products; prior to the dramatic 
commercial success of Rituxan® and Herceptin®, Big Pharma viewed 
monoclonal antibodies as research reagents that could not be developed as 
financially and therapeutically successful products. Humira® was the top-
selling drug in the world in 2012 at $9.6B in total sales with 2018 sales 
projected to be $12.8B.12 
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Not only are biologics projected to comprise an ever greater component of 
the biopharmaceutical product mix, they are also providing what are arguably 
the most exciting treatment effects in recent clinical trials.  Recent regulatory 
approval of the antibody-drug conjugate products Adcetris™ and Kadcyla® 
were assured based on impressive clinical outcomes in lymphoma3 and breast 
cancer,4 respectively.  Response rates in late-stage metastatic melanoma for the 
immunotherapy monoclonal antibodies MK-3475 and nivolumab are 
unprecedented with responses anticipated to be highly durable after cessation 
of treatment.5  It is this kind of meaningful benefit to patients that is sure to 
drive continued growth of biologics over the years and decades to come.  
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